Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

General Research Article

The Interaction of the Microtubule Targeting Anticancer Drug Colchicine with Human Glutathione Transferases

Author(s): Georgios Premetis, Panagiotis Marugas, Georgios Fanos, Dimitrios Vlachakis, Evangelia G. Chronopoulou, Fereniki Perperopoulou, Kashyap Kumar Dubey, Pratyoosh Shukla, Ahmed Ibrahim Foudah, Magdy Mohamed Muharram, Mohammed F. Aldawsari, Anastassios C. Papageorgiou and Nikolaos E. Labrou*

Volume 26 , Issue 40 , 2020

Page: [5205 - 5212] Pages: 8

DOI: 10.2174/1381612826666200724154711

Price: $65

Abstract

Background: Glutathione transferases (GSTs) are a family of Phase II detoxification enzymes that have been shown to be involved in the development of multi-drug resistance (MDR) mechanism toward chemotherapeutic agents. GST inhibitors have, therefore, emerged as promising chemosensitizers to manage and reverse MDR. Colchicine (COL) is a classical antimitotic, tubulin-binding agent (TBA) which is being explored as anticancer drug.

Methods: In the present work, the interaction of COL and its derivative 2,3-didemethylcolchicine (2,3-DDCOL) with human glutathione transferases (hGSTA1-1, hGSTP1-1, hGSTM1-1) was investigated by inhibition analysis, molecular modelling and molecular dynamics simulations.

Results: The results showed that both compounds bind reversibly to human GSTs and behave as potent inhibitors. hGSTA1-1 was the most sensitive enzyme to inhibition by COL with IC50 22 μΜ. Molecular modelling predicted that COL overlaps with both the hydrophobic (H-site) and glutathione binding site (G-site) and polar interactions appear to be the driving force for its positioning and recognition at the binding site. The interaction of COL with other members of GST family (hGSTA2-2, hGSTM3-3, hGSTM3-2) was also investigated with similar results.

Conclusion: The results of the present study might be useful in future drug design and development efforts towards human GSTs.

Keywords: Cancer, colchicine, glutathione transferase, multi-drug resistance, Phase II detoxification enzymes, antimitotic.

[1]
Sawers L, Ferguson MJ, Ihrig BR, et al. Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines. Br J Cancer 2014; 111(6): 1150-8.
[http://dx.doi.org/10.1038/bjc.2014.386] [PMID: 25010864]
[2]
Backos DS, Franklin CC, Reigan P. The role of glutathione in brain tumor drug resistance. Biochem Pharmacol 2012; 83(8): 1005-12.
[http://dx.doi.org/10.1016/j.bcp.2011.11.016] [PMID: 22138445]
[3]
Ramsay EE, Dilda PJ. Glutathione S-conjugates as prodrugs to target drug-resistant tumors. Front Pharmacol 2014; 5: 181.
[http://dx.doi.org/10.3389/fphar.2014.00181] [PMID: 25157234]
[4]
Karpusas M, Axarli I, Chiniadis L, et al. The interaction of the chemotherapeutic drug chlorambucil with human glutathione transferase A1-1: kinetic and structural analysis. PLoS One 2013; 8(2)e56337
[http://dx.doi.org/10.1371/journal.pone.0056337] [PMID: 23460799]
[5]
Allocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases. Oncogenesis 2018; 7(1): 8.
[http://dx.doi.org/10.1038/s41389-017-0025-3] [PMID: 29362397]
[6]
De Luca A, Federici L, De Canio M, Stella L, Caccuri AM. New insights into the mechanism of JNK1 inhibition by glutathione transferase P1-1. Biochemistry 2012; 51(37): 7304-12.
[http://dx.doi.org/10.1021/bi300559m] [PMID: 22920299]
[7]
Laborde E. Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. ll Death and Differentiation 2010; 17: 373-1380.
[8]
Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003; 22(47): 7369-75.
[http://dx.doi.org/10.1038/sj.onc.1206940] [PMID: 14576844]
[9]
Tew KD, Townsend DM. Glutathione-s-transferases as determinants of cell survival and death. Antioxid Redox Signal 2012; 17(12): 1728-37.
[http://dx.doi.org/10.1089/ars.2012.4640] [PMID: 22540427]
[10]
Checa-Rojas A, Delgadillo-Silva LF, Velasco-Herrera MDC, et al. GSTM3 and GSTP1: novel players driving tumor progression in cervical cancer. Oncotarget 2018; 9(31): 21696-714.
[http://dx.doi.org/10.18632/oncotarget.24796] [PMID: 29774096]
[11]
Sau A, Pellizzari Tregno F, Valentino F, Federici G, Caccuri AM. Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys 2010; 500(2): 116-22.
[http://dx.doi.org/10.1016/j.abb.2010.05.012] [PMID: 20494652]
[12]
Li WS, Lam WS, Liu KC, et al. Overcoming the drug resistance in breast cancer cells by rational design of efficient glutathione S-transferase inhibitors. Org Lett 2010; 12(1): 20-3.
[http://dx.doi.org/10.1021/ol902298s] [PMID: 19961147]
[13]
Georgakis ND, Karagiannopoulos DA, Thireou TN, et al. Concluding the trilogy: The interaction of 2,2′-dihydroxy-benzophenones and their carbonyl N-analogues with human glutathione transferase M1-1 face to face with the P1-1 and A1-1 isoenzymes involved in MDR. Chem Biol Drug Des 2017; 90(5): 900-8.
[http://dx.doi.org/10.1111/cbdd.13011] [PMID: 28440951]
[14]
Zompra A, Georgakis N, Pappa E, et al. Glutathione analogues as substrates or inhibitors that discriminate between allozymes of the MDR-involved human glutathione transferase P1-1. Biopolymers 2016; 106(3): 330-44.
[http://dx.doi.org/10.1002/bip.22844] [PMID: 27037874]
[15]
Pouliou FM, Thireou TN, Eliopoulos EE, Tsoungas PG, Labrou NE, Clonis YD. Isoenzyme- and allozyme-specific inhibitors: 2,2′-dihydroxybenzophenones and their carbonyl N-analogues that discriminate between human glutathione transferase A1-1 and P1-1 allozymes. Chem Biol Drug Des 2015; 86(5): 1055-63.
[http://dx.doi.org/10.1111/cbdd.12574] [PMID: 25891019]
[16]
Perperopoulou FD, Tsoungas PG, Thireou TN, et al. 2,2′-Dihydroxybenzophenones and their carbonyl N-analogues as inhibitor scaffolds for MDR-involved human glutathione transferase isoenzyme A1-1. Bioorg Med Chem 2014; 22(15): 3957-70.
[http://dx.doi.org/10.1016/j.bmc.2014.06.007] [PMID: 25002233]
[17]
Chronopoulou EG, Ataya F, Labrou NE. A Microplate-based Platform with Immobilized Human Glutathione Transferase A1-1 for High-throughput screening of plant-origin Inhibitors. Curr Pharm Biotechnol 2018; 19(11): 925-31.
[http://dx.doi.org/10.2174/1389201019666181029103538] [PMID: 30370843]
[18]
Almatroudi A, Alsahli MA, Alrumaihi F, Allemailem KS, Rahmani AH. Ginger: a novel strategy to battle cancer through modulating cell signalling pathways: a review. Curr Pharm Biotechnol 2019; 20(1): 5-16.
[http://dx.doi.org/10.2174/1389201020666190119142331] [PMID: 30659535]
[19]
Lv H, Zhen C, Liu J, Yang P, Hu L, Shang P. Unraveling the potential role of glutathione in multiple forms of cell death in cancer therapy. Oxid Med Cell Longev 2019; 20193150145
[http://dx.doi.org/10.1155/2019/3150145] [PMID: 31281572]
[20]
Zou M, Hu X, Xu B, et al. Glutathione Stransferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer. Oncol Rep 2019; 41(2): 989-98.
[PMID: 30431119]
[21]
Bocedi A, Fabrini R, Farrotti A, et al. The impact of nitric oxide toxicity on the evolution of the glutathione transferase superfamily: a proposal for an evolutionary driving force. J Biol Chem 2013; 288(34): 24936-47.
[http://dx.doi.org/10.1074/jbc.M113.476135] [PMID: 23828197]
[22]
Ertan-Bolelli T, Musdal Y, Bolelli K, et al. Synthesis and biological evaluation of 2-substituted-5-(4-nitrophenylsulfonamido)benzoxazoles as human GST P1-1 inhibitors, and description of the binding site features. ChemMedChem 2014; 9(5): 984-92.
[http://dx.doi.org/10.1002/cmdc.201400010] [PMID: 24677708]
[23]
Oakley AJ, Lo Bello M, Nuccetelli M, Mazzetti AP, Parker MW. The ligandin (non-substrate) binding site of human Pi class glutathione transferase is located in the electrophile binding site (H-site). J Mol Biol 1999; 291(4): 913-26.
[http://dx.doi.org/10.1006/jmbi.1999.3029] [PMID: 10452896]
[24]
Ertan-Bolelli T, Bolelli K, Musdal Y, et al. Design and synthesis of 2-substituted-5-(4-trifluoromethylphenyl-sulphonamido)benzoxazole derivatives as human GST P1-1 inhibitors. Artif Cells Nanomed Biotechnol 2017; 14: 1-8.
[PMID: 28503938]
[25]
Wang HB, Jin XL, Zheng JF, Wang F, Dai F, Zhou B. Developing piperlongumine-directed glutathione S-transferase inhibitors by an electrophilicity-based strategy. Eur J Med Chem 2017; 126: 517-25.
[http://dx.doi.org/10.1016/j.ejmech.2016.11.034] [PMID: 27914365]
[26]
Chronopoulou E, Papageorgiou AC, Markoglou A, Labrou NE. Inhibition of human glutathione transferases by pesticides: Development of a simple analytical assay for the quantification of pesticides in water. J Mol Catal, B Enzym 2012; 81: 43-51.
[http://dx.doi.org/10.1016/j.molcatb.2012.04.022]
[27]
Dubey KK, Kumar P, Labrou NE, Shukla P. Biotherapeutic potential and mechanisms of action of colchicine. Crit Rev Biotechnol 2017; 37(8): 1038-47.
[http://dx.doi.org/10.1080/07388551.2017.1303804] [PMID: 28436240]
[28]
Kerekes P, Sharma PN, Brossi A, Chignell CF, Quinn FR. Synthesis and biological effects of novel thiocolchicines. 3. Evaluation of N-acyldeacetylthiocolchicines, N-(alkoxycarbonyl) deacetylthiocolchicines, and O-ethyldemethylthiocolchicines. New synthesis of thiodemecolcine and antileukemic effects of 2-demethyl- and 3-demethylthiocolchicine. J Med Chem 1985; 28(9): 1204-8.
[http://dx.doi.org/10.1021/jm00147a014] [PMID: 4032423]
[29]
De Vincenzo R, Ferlini C, Distefano M, et al. In vitro evaluation of newly developed chalcone analogues in human cancer cells. Cancer Chemother Pharmacol 2000; 46(4): 305-12.
[http://dx.doi.org/10.1007/s002800000160] [PMID: 11052628]
[30]
Dubey KK, Jawed A, Haque S. Enhanced extraction of 3-demethylated colchicine from fermentation broth of Bacillus megaterium by optimization of process parameters through statistical experimental design. Eng Life Sci 2011; 11(6): 598-606.
[http://dx.doi.org/10.1002/elsc.201000207]
[31]
Khan S, Jawed A, Dubey KK, Wahid M, Khan M, Haque S. Constrained azeotropic optimization of extraction system components for safe and efficient recovery of desired metabolite (e.g., 3-demethylated colchicine). RSC Advances 2016; 6(42): 35498-506.
[http://dx.doi.org/10.1039/C5RA26608D]
[32]
Rana TM. Artificial proteolysis by a metal chelate: methodology and mechanism. Adv Inorg Biochem 1994; 10: 177-200.
[PMID: 8203288]
[33]
Bradford M. A rapid and sensitive method for the detection of microgram quantities of proteins. Anal Biochem 1976; 72: 248-54.
[http://dx.doi.org/10.1016/0003-2697(76)90527-3] [PMID: 942051]
[34]
Molecular Operating Environment (MOE), 2013. 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7: Chemical Computing Group ULC 2018; 08
[35]
Vlachakis D, Tsagrasoulis D, Megalooikonomou V, Kossida S. Introducing Drugster: a comprehensive and fully integrated drug design, lead and structure optimization toolkit. Bioinformatics 2013; 29(1): 126-8.
[http://dx.doi.org/10.1093/bioinformatics/bts637] [PMID: 23104887]
[36]
Vlachakis D, Fakourelis P, Megalooikonomou V, Makris C, Kossida S. DrugOn: a fully integrated pharmacophore modeling and structure optimization toolkit. PeerJ 2015; 3e725
[http://dx.doi.org/10.7717/peerj.725] [PMID: 25648563]
[37]
Pljesa-Ercegovac M, Savic-Radojevic A, Matic M, et al. Glutathione transferases: potential targets to overcome chemoresistance in solid tumors. Int J Mol Sci 2018; 19(12): 3785.
[http://dx.doi.org/10.3390/ijms19123785] [PMID: 30487385]
[38]
Dalmizrak O, Teralı K, Asuquo EB, Ogus IH, Ozer N. The relevance of glutathione reductase inhibition by fluoxetine to human health and disease: Insights derived from a combined kinetic and docking study. Protein J 2019; 38(5): 515-24.
[http://dx.doi.org/10.1007/s10930-019-09834-7] [PMID: 31004256]
[39]
Eklund BI, Moberg M, Bergquist J, Mannervik B. Divergent activities of human glutathione transferases in the bioactivation of azathioprine. Mol Pharmacol 2006; 70(2): 747-54.
[http://dx.doi.org/10.1124/mol.106.025288] [PMID: 16717136]
[40]
Pan XD, Yang ZP, Tang QL, et al. Expression and function of GSTA1 in lung cancer cells. Asian Pac J Cancer Prev 2014; 15(20): 8631-5.
[http://dx.doi.org/10.7314/APJCP.2014.15.20.8631] [PMID: 25374180]
[41]
Liu H, Yang Z, Zang L, et al. Downregulation of Glutathione S-transferase A1 suppressed tumor growth and induced cell apoptosis in A549 cell line. Oncol Lett 2018; 16(1): 467-74.
[http://dx.doi.org/10.3892/ol.2018.8608] [PMID: 29928434]
[42]
De Luca A, Parker LJ, Ang WH, et al. A structure-based mechanism of cisplatin resistance mediated by glutathione transferase P1-1. Int J Mol Sci 2018; 19(12): 3785.
[43]
Punganuru SR, Madala HR, Srivenugopal KS. Colchicine-based hybrid anticancer drugs to combat tumor heterogeneity. Med Chem 2016; 6: 165-73.
[44]
Wu X, Wang Q, Li W. Recent advances in heterocyclic tubulin inhibitors targeting the colchicine binding site. Anticancer Agents Med Chem 2016; 16(10): 1325-38.
[http://dx.doi.org/10.2174/1871520616666160219161921] [PMID: 26899186]
[45]
Depeille P, Cuq P, Mary S, et al. Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol Pharmacol 2004; 65(4): 897-905.
[http://dx.doi.org/10.1124/mol.65.4.897] [PMID: 15044619]
[46]
Meding S, Balluff B, Elsner M, et al. Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol 2012; 228(4): 459-70.
[http://dx.doi.org/10.1002/path.4021] [PMID: 22430872]
[47]
Mitra AP, Pagliarulo V, Yang D, et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol 2009; 27: 3929-37.
[http://dx.doi.org/10.1200/JCO.2008.18.5744]
[48]
Lin JH, Tu SH, Chen LC, et al. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells. Breast Cancer Res Treat 2018; 172(1): 45-59.
[http://dx.doi.org/10.1007/s10549-018-4897-5] [PMID: 30054830]

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy